Sorry not trying to clutter thread but yeah flynnal..
A new sleeping pill is coming to town:
"Eplivanserin's developer, Sanofi-Aventis, is gearing up for the European launch of the drug in 2009 based upon favorable comments from the European drug agency. In addition, the company, which has funded three completed phase III clinical trials, is preparing to file for marketing approval in the United States and Canada, Pierre Gervais said at the annual American Psychiatric Association Institute on Psychiatric Services.
Eplivanserin is the furthest along in development of a new nonsedating drug class known as ASTARs, or Antagonists of Serotonin Two A Receptors. Many sleep disorder experts expect the ASTARs to take over a major chunk of the insomnia treatment market now dominated by zolpidem and other drugs acting on the GABA-A receptor, said Mr. Gervais, a pharmacist at Q&T Research of Sherbrooke, Quebec, an independent clinical research firm hired by Sanofi-Aventis to participate in an eplivanserin trial.
He reported on a trial of 351 adults with chronic insomnia who were randomized double blind to 4 weeks of either 1 mg or 5 mg of eplivanserin or placebo in the evening. The 5-mg dose, which is what will be marketed, resulted in a mean 39-minute reduction in the baseline 84-minute wake time after sleep onset. This was significantly greater than the mean 26-minute reduction with placebo.
Also, eplivanserin at 5 mg/day resulted in a 64% reduction in the number of nocturnal awakenings, compared with a 36% decrease with placebo. More eplivanserin-treated patients reported a significant improvement in the refreshing quality of sleep.
The side effect profile of eplivanserin mimicked that of placebo. The exception was dry mouth, which was reported by 1.7% of the placebo group and 5.3% of patients on 5 mg/day of eplivanserin.
The ASTAR was not associated with next-morning drowsiness or difficulty in concentration."
In some regards it might be because there was health risks related to a specific compound that one of the drugs didn't make it through but 5-HT2As are an amazing option. That we don't really actually have because they never made it to market.
A meta study can be found here if anybody is interested in these 5-HT2A antagonist/reverse agonists
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630942/
That was written some of the people that helped with some of these newer really effective drugs (ACADIA pharm) and I swear at some points they are pointing out that its suspicious.. "It remains an enigma that 5-HT
2A receptor antagonists have such profound effects on sleep, yet so many drugs have failed in larger efficacy trials or have failed to show a sufficiently robust benefit to risk ratio in clinical trials" and "Hypnion reported that HY10275, a dual-acting H
1 receptor antagonist and 5-HT
2A receptor antagonist, improves sleep in patients with transient insomnia (Hypnion press release, January 5, 2007) before the company was acquired by Eli Lilly in April 2007. Since then, Lilly has discontinued clinical development of pruvanserin, its selective 5-HT
2A receptor antagonist"
HMMMMMM. There are mainly just drugs that hit 5-HT2A as a passerby right now and aren't selective for it, like Avanza/Mirtazapine, Seroquel/trazadone. Except Pimavanserin from ACADIA got breakthrough drug status for Parkinson's psychosis and that seems to be a wonder drug. But yeah keep an eye out for 5-HT2A related drugs. That meta study above mentions improvements in depression a lot after treatment of insomnia and its comorbidity with insomnia . Peace